Lonza plant issue to result in shortage of Ipsen's Increlex; Woodcock uncertain of inspections' effectiveness;

> Issues at a Lonza plant in Hopkinton, MA, will result in a shortage through this year of Ipsen's Increlex, a treatment for children who are very short for their age. Release

> Lonza says it will close its Niacin production plant in Visp, Switzerland, for a few weeks beginning in May for routine maintenance work. Item

> The FDA has released a new final guidance document regarding how regulators plan to classify pharmaceutical products that are made of solid-state cocrystals. Story

> Taiwanese drugmaker Adimmune Corp. said it expects to be able to manufacture up to 3 million doses against the H7N9 avian influenza virus by August, after a case of the deadly disease was diagnosed in that country. Story

> The FDA has recalled more compounded sterile injectable drugs. Announcement

> BioOutsource, a provider of contract testing services, has opened a new facility in Cambridge, MA, that will provide bioanalytical and biosafety services. Release

> Australia has won the coveted ruling by the European Commission that its API manufacturing meets EU standards, and so imports from there will not require certifications. Announcement

> FDA's Janet Woodcock says she is not sure how effective the agency's inspection program is. Blog post

And finally... Hospira ($HSP) this week marked 5 years of manufacturing biosimilars for the European market, having launched Retacrit, a recombinant human erythropoietin, or "EPO biosimilar," in early 2008. Release